Lakewood-Amedex Biotherapeutics (LABT) investor relations material

Company overview and business model

• Focuses on developing novel Bisphosphocin® antimicrobials to address unmet needs in infectious diseases, especially those driven by antimicrobial resistance (AMR).

• Lead product, Nu-3 gel, targets infected diabetic foot ulcers (iDFU) with a topical formulation designed for rapid, broad-spectrum action and minimal resistance development.

• Pipeline includes additional Bisphosphocin® compounds (Nu-8, Nu-10, Nu-11) for urinary tract and pulmonary infections.

• Holds 68 issued and 36 pending patents covering core technologies and product candidates in major markets.

• Operates as a clinical-stage biopharmaceutical company, outsourcing manufacturing and focusing resources on R&D and IP protection.

Financial performance and metrics

• Reported net losses of $3.8 million in 2025 and $4.8 million in 2024, with an accumulated deficit of $53.4 million as of December 31, 2025.

• Cash and cash equivalents were approximately $0.2 million at year-end 2025, with a working capital deficit of $2.1 million.

• Raised $46.1 million in gross proceeds since inception through equity and convertible debt.

• Auditors expressed substantial doubt about the company’s ability to continue as a going concern.

• R&D expenses decreased to $1.3 million in 2025, while G&A expenses increased to $2.5 million.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from recent financings are allocated to clinical development of Nu-3 and pipeline advancement.

• Recent $7.5 million Series C Preferred Stock financing intended to fund Phase 2a clinical trial for Nu-3 gel.

• Ongoing need for additional capital to support R&D, regulatory, and commercialization activities.